Treg Depletion Inhibits Efficacy of Cancer Immunotherapy: Implications for Clinical Trials

Background Regulatory T lymphocytes (Treg) infiltrate human glioblastoma (GBM); are involved in tumor progression and correlate with tumor grade. Transient elimination of Tregs using CD25 depleting antibodies (PC61) has been found to mediate GBM regression in preclinical models of brain tumors. Clinical trials that combine Treg depletion with tumor vaccination are underway to determine whether transient Treg depletion can enhance anti-tumor immune responses and improve long term survival in cancer patients. Findings Using a syngeneic intracrabial glioblastoma (GBM) mouse model we show that systemic depletion of Tregs 15 days after tumor implantation using PC61 resulted in a decrease in Tregs present in tumors, draining lymph nodes and spleen and improved long-term survival (50% of mice survived >150 days). No improvement in survival was observed when Tregs were depleted 24 days after tumor implantation, suggesting that tumor burden is an important factor for determining efficacy of Treg depletion in clinical trials. In a T cell dependent model of brain tumor regression elicited by intratumoral delivery of adenoviral vectors (Ad) expressing Fms-like Tyrosine Kinase 3 ligand (Flt3L) and Herpes Simplex Type 1-Thymidine Kinase (TK) with ganciclovir (GCV), we demonstrate that administration of PC61 24 days after tumor implantation (7 days after treatment) inhibited T cell dependent tumor regression and long term survival. Further, depletion with PC61 completely inhibited clonal expansion of tumor antigen-specific T lymphocytes in response to the treatment. Conclusions Our data demonstrate for the first time, that although Treg depletion inhibits the progression/eliminates GBM tumors, its efficacy is dependent on tumor burden. We conclude that this approach will be useful in a setting of minimal residual disease. Further, we also demonstrate that Treg depletion, using PC61 in combination with immunotherapy, inhibits clonal expansion of tumor antigen-specific T cells, suggesting that new, more specific targets to block Tregs will be necessary when used in combination with therapies that activate anti-tumor immunity.

[1]  T. Taniguchi,et al.  The IL-2 IL-2 receptor system: A current overview , 1993, Cell.

[2]  M. Lesniak,et al.  An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. , 2006, Neuro-oncology.

[3]  W. Murphy,et al.  Suppression of natural killer cell-mediated bone marrow cell rejection by CD4+CD25+ regulatory T cells. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[4]  R. Schreiber,et al.  The immunobiology of cancer immunosurveillance and immunoediting. , 2004, Immunity.

[5]  W. Debinski,et al.  EphA2 as a Novel Molecular Marker and Target in Glioblastoma Multiforme , 2005, Molecular Cancer Research.

[6]  C. Barcia,et al.  Fms-Like Tyrosine Kinase 3 Ligand Recruits Plasmacytoid Dendritic Cells to the Brain1 , 2006, The Journal of Immunology.

[7]  H. Lassmann,et al.  Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: Implications for clinical trials , 1999, Nature Medicine.

[8]  J. Lowenthal,et al.  Similarities between interleukin-2 receptor number and affinity on activated B and T lymphocytes , 1985, Nature.

[9]  J. Lowenthal,et al.  High and low affinity IL 2 receptors: analysis by IL 2 dissociation rate and reactivity with monoclonal anti-receptor antibody PC61. , 1985, Journal of immunology.

[10]  Timothy F. Cloughesy,et al.  Dendritic Cell Vaccination in Glioblastoma Patients Induces Systemic and Intracranial T-cell Responses Modulated by the Local Central Nervous System Tumor Microenvironment , 2005, Clinical Cancer Research.

[11]  A. Carpentier,et al.  Recent advances in immunotherapy for human glioma , 2006, Current opinion in oncology.

[12]  D. Bigner,et al.  Systemic CTLA-4 Blockade Ameliorates Glioma-Induced Changes to the CD4+ T Cell Compartment without Affecting Regulatory T-Cell Function , 2007, Clinical Cancer Research.

[13]  C. Barcia,et al.  Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model. , 2008, Neuro-oncology.

[14]  R. Schreiber,et al.  The three Es of cancer immunoediting. , 2004, Annual review of immunology.

[15]  T. Schumacher,et al.  Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses , 2001, The Journal of experimental medicine.

[16]  T. Whiteside,et al.  Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. , 2006, Seminars in cancer biology.

[17]  P. Kleihues,et al.  Epidemiology and etiology of gliomas , 2005, Acta Neuropathologica.

[18]  David J. Yang,et al.  The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. , 2006, Neuro-oncology.

[19]  J. Skog.  Glioma-specific antigens for immune tumor therapy , 2006, Expert review of vaccines.

[20]  L. Liau,et al.  Cellular immunity and immunotherapy of brain tumors. , 2004, Frontiers in bioscience : a journal and virtual library.

[21]  A. Friedman,et al.  Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. , 2006, Cancer research.

[22]  C. Barcia,et al.  Inflammatory and anti-glioma effects of an adenovirus expressing human soluble Fms-like tyrosine kinase 3 ligand (hsFlt3L): treatment with hsFlt3L inhibits intracranial glioma progression. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[23]  J. Blattman,et al.  Cancer Immunotherapy: A Treatment for the Masses , 2004, Science.

[24]  K. Hoang-Xuan,et al.  Primary brain tumours in adults , 2003, The Lancet.

[25]  M. Lesniak,et al.  CD4+CD25+FoxP3+ T-cell infiltration and heme oxygenase-1 expression correlate with tumor grade in human gliomas , 2007, Journal of Neuro-Oncology.

[26]  Yong Zhao,et al.  Regulatory CD4+CD25+ T-cells are Controlled by Multiple Pathways at Multiple Levels , 2007, International reviews of immunology.

[27]  A. Ribas,et al.  Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model. , 2005, Cancer research.

[28]  C. Kruse,et al.  Mechanisms of malignant glioma immune resistance and sources of immunosuppression. , 2006, Gene therapy & molecular biology.

[29]  M. Colombo,et al.  Regulatory T-cell inhibition versus depletion: the right choice in cancer immunotherapy , 2007, Nature Reviews Cancer.

[30]  L. Sun,et al.  Presence of Functional Mouse Regulatory CD4+CD25+T Cells in Xenogeneic Neonatal Porcine Thymus‐Grafted Athymic Mice , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[31]  A. Rudensky,et al.  Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice , 2007, Nature Immunology.

[32]  Mitsugu Maéno,et al.  Expression and Function of Xmsx-2B in Dorso-Ventral Axis Formation in Gastrula Embryos , 2000, Zoological science.

[33]  C Haanen,et al.  A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. , 1995, Journal of immunological methods.

[34]  M. Lesniak,et al.  Prolongation of survival following depletion of CD4+CD25+ regulatory T cells in mice with experimental brain tumors. , 2006, Journal of neurosurgery.

[35]  P. Lowenstein.  Immunology of viral-vector-mediated gene transfer into the brain: an evolutionary and developmental perspective. , 2002, Trends in immunology.

[36]  P. Lowenstein,et al.  Combining cytotoxic and immune-mediated gene therapy to treat brain tumors. , 2005, Current topics in medicinal chemistry.

[37]  G. Palù,et al.  Clinical trials of gene therapy, virotherapy, and immunotherapy for malignant gliomas , 2006, Cancer Gene Therapy.

[38]  R. Steinman,et al.  Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor , 1992, The Journal of experimental medicine.

[39]  P. Lowenstein,et al.  Gene therapy and targeted toxins for glioma : Gene therapy for cancer , 2005 .

[40]  Yong Zhao,et al.  The phenotypic characterization of naturally occurring regulatory CD4+CD25+ T cells. , 2006, Cellular & molecular immunology.

[41]  L. Zitvogel,et al.  The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression , 2006, Immunological reviews.

[42]  V. Perry,et al.  What is immune privilege (not)? , 2007, Trends in immunology.

[43]  D. Andrews,et al.  Glioblastoma Patients Exhibit Circulating Tumor-Specific CD8+ T Cells , 2005, Clinical Cancer Research.

[44]  Edward C Halperin,et al.  Is the long‐term survival of patients with intracranial glioblastoma multiforme overstated? , 2003, Cancer.

[45]  R. Tanaka,et al.  Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial , 2003, British Journal of Cancer.

[46]  J. Casanova,et al.  X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy , 2001, Nature Genetics.

[47]  T. Fujita,et al.  Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. , 1999, Cancer research.

[48]  L. Boon,et al.  CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo , 2007, International journal of cancer.

[49]  M. Smyth,et al.  CD4+CD25+ T Regulatory Cells Suppress NK Cell-Mediated Immunotherapy of Cancer1 , 2006, The Journal of Immunology.

[50]  Bryon D Johnson,et al.  CD25+ Regulatory T Cell Inhibition Enhances Vaccine-induced Immunity to Neuroblastoma , 2007, Journal of immunotherapy.

[51]  D. Bigner,et al.  Systemic Anti-CD25 Monoclonal Antibody Administration Safely Enhances Immunity in Murine Glioma without Eliminating Regulatory T Cells , 2006, Clinical Cancer Research.

[52]  C. Thompson,et al.  Expression and function of CTLA-4 in Th1 and Th2 cells. , 1998, Journal of immunology.